Drugs in Dev. Endocrinology
Phase III
South Korea 
Lead Product(s) : Eftansomatropin Alpha
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : I-Mab Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Genexine’s long-acting growth hormone meets Phase 3 primary endpoint
Details : Genexine’s, GX-H9, a proprietary long-acting growth hormone shows positive topline results from phase 3 study for growth hormone deficiency, is being conducted in China with I-Mab.
Product Name : GX-H9
Product Type : Hormone
Upfront Cash : Inapplicable
August 30, 2023
Lead Product(s) : Eftansomatropin Alpha
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : I-Mab Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enavogliflozin,Gemigliptin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enavogliflozin is an SGLT-2 inhibitor for diabetes in development by Daewoong for the first time in South Korea. The safety of Enavogliflozin has been proven through three sequential clinical trials of monotherapy, metformin combination, and Metformin-Ge...
Product Name : DWP16001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2022
Lead Product(s) : Enavogliflozin,Gemigliptin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enavogliflozin,Gemigliptin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DWP16001 (enavogliflozin) is a new diabetes drug in the SGLT-2 inhibitor class. The two combination trials, Enavogliflozin-Metformin and Enavogliflozin-Metformin-Gemigliptin combination, demonstrated non-inferiority in HbAc1 change compared to dapagliflo...
Product Name : DWP16001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : Enavogliflozin,Gemigliptin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enavogliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the study, researchers compared fructosamine, fasting glucose, and insulin dose changes in a group treated with insulin and Enavogliflozin once daily for eight weeks and the other group once every three days to evaluate its weight and blood pressure.
Product Name : DWP16001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Enavogliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
